Fracture healing with alendronate treatment in the Brtl/ plus mouse model of osteogenesis imperfecta

被引:19
|
作者
Meganck, J. A. [1 ,2 ]
Begun, D. L. [1 ,2 ]
McElderry, J. D. [3 ]
Swick, A. [1 ,2 ]
Kozloff, K. M. [1 ,2 ]
Goldstein, S. A. [1 ,2 ]
Morris, M. D. [3 ]
Marini, J. C. [4 ]
Caird, M. S. [1 ]
机构
[1] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
[4] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
Osteogenesis imperfecta; Bisphosphonates; Bone; Rodent; Fracture repair; HYPERPLASTIC CALLUS FORMATION; POLARIZED-LIGHT MICROSCOPY; ZOLEDRONIC ACID; BISPHOSPHONATE INCADRONATE; BONE STRENGTH; CHILDREN; PAMIDRONATE; COLLAGEN; REPAIR; RATS;
D O I
10.1016/j.bone.2013.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of bisphosphonate administration. This study investigated the effect of alendronate, a potent aminobisphosphonate, on fracture healing. Using the Brtl/+ murine model of type IV OI, tibial fractures were generated in 8-week-old mice that were untreated, treated with alendronate before fracture, or treated before and after fracture. After 2, 3, or 5 weeks of healing, tibiae were assessed using microcomputed tomography (mu CT), torsion testing, quantitative histomorphometry, and Raman microspectroscopy. There were no morphologic, biomechanical or histomorphometric differences in callus between untreated mice and mice that received alendronate before fracture. Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus. Both Brtl/+ and WT mice that received alendronate before and after fracture had increases in the callus volume, bone volume fraction and torque at failure after 5 weeks of healing. Raman microspectroscopy results did not show any effects of alendronate in wild-type mice, but calluses from Brtl+ mice treated with alendronate during healing had a decreased mineral-to-matrix ratio, decreased crystallinity and an increased carbonate-to-phosphate ratio. Treatment with alendronate altered the dynamics of healing by preventing callus volume decreases later in the healing process. Fracture healing in Brtl/+ untreated animals was not significantly different from animals in which alendronate was halted at the time of fracture. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [41] How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model
    Mehta, Shivam
    Wang, Ke
    Chen, Po-Jung
    Zhichao, Fan
    Ahmida, Ahmad
    Kalajzic, Zana
    Yadav, Sumit
    EUROPEAN JOURNAL OF ORTHODONTICS, 2023, 45 (02) : 217 - 223
  • [42] Early Fracture Healing is Delayed in the Col1a2+/G610C Osteogenesis Imperfecta Murine Model
    Roberta Besio
    Silvia Maruelli
    Severine Battaglia
    Laura Leoni
    Simona Villani
    Pierre Layrolle
    Antonio Rossi
    Valerie Trichet
    Antonella Forlino
    Calcified Tissue International, 2018, 103 : 653 - 662
  • [43] Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta
    Rousseau, Julie
    Gioia, Roberta
    Layrolle, Pierre
    Lieubeau, Blandine
    Heymann, Dominique
    Rossi, Antonio
    Marini, Joan C.
    Trichet, Valerie
    Forlino, Antonella
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2014, 22 (05) : 667 - 674
  • [44] Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta
    Evans, KD
    Lau, ST
    Oberbauer, AM
    Martin, RB
    BONE, 2003, 32 (03) : 268 - 274
  • [45] Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen
    Biggin, Andrew
    Briody, Julie N.
    Ormshaw, Elizabeth
    Wong, Karen K. Y.
    Bennetts, Bruce H.
    Munns, Craig F.
    HORMONE RESEARCH IN PAEDIATRICS, 2014, 81 (03): : 204 - 210
  • [46] Irisin reduces bone fracture by facilitating osteogenesis and antagonizing TGF-8/Smad signaling in a growing mouse model of osteogenesis imperfecta
    Sun, Bin
    Wu, Huiqiao
    Lu, Jiajia
    Zhang, Rongcheng
    Shen, Xiaolong
    Gu, Yifei
    Shi, Changgui
    Zhang, Ying
    Yuan, Wen
    JOURNAL OF ORTHOPAEDIC TRANSLATION, 2023, 38 : 175 - 189
  • [47] EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA
    Lv, Fang
    Liu, Yi
    Xu, Xiaojie
    Wang, Jianyi
    Ma, Doudou
    Jiang, Yan
    Wang, Ou
    Xia, Weibo
    Xing, Xiaoping
    Yu, Wei
    Li, Mei
    ENDOCRINE PRACTICE, 2016, 22 (12) : 1369 - 1376
  • [48] Inhibition of TGF-β Increases Bone Volume and Strength in a Mouse Model of Osteogenesis Imperfecta
    Greene, Benjamin
    Russo, Ryan J.
    Dwyer, Shannon
    Malley, Katie
    Roberts, Errin
    Serrielo, Joseph
    Piepenhagen, Peter
    Cummings, Sheila
    Ryan, Susan
    Zarazinski, Christine
    Uppuganti, Sasidhar
    Bukanov, Nikolai
    Nyman, Jeffry S.
    Cox, Megan K.
    Liu, Shiguang
    Ibraghimov-Beskrovnaya, Oxana
    Sabbagh, Yves
    JBMR PLUS, 2021, 5 (09)
  • [49] Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta
    Little, David G.
    Peacock, Lauren
    Mikulec, Kathy
    Kneissel, Michaela
    Kramer, Ina
    Cheng, Tegan L.
    Schindeler, Aaron
    Munns, Craig
    BONE, 2017, 101 : 96 - 103
  • [50] Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study
    Ward, L. M.
    Rauch, F.
    Whyte, M. P.
    D'Astous, J.
    Gates, P. E.
    Grogan, D.
    Lester, E. L.
    McCall, R. E.
    Pressly, T. A.
    Sanders, J. O.
    Smith, P. A.
    Steiner, R. D.
    Sullivan, E.
    Tyerman, G.
    Smith-Wright, D. L.
    Verbruggen, N.
    Heyden, N.
    Lombardi, A.
    Glorieux, F. H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (02) : 355 - 364